301408.SHE Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
- Market cap
- CNY 5.66B
- P/E
- 22.1x
- P/B
- 2.47x
- ROE
- 13.1%
- Dividend yield
- 1.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301408.SHE undervalued?
Graham number301408.SHE trades 55.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A fundamental analysis
No fundamental analysis for Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A yet.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
Anhui Huaren Health Pharmaceutical Co., Ltd. operates in the medical and healthcare industry. It offers products for oral and throat, nourishing, heat-clearing, respiratory system, and gynecology, as well as provides vitamins and minerals, and detoxifying products. In addition, it provides supplements, and nutrition and health products. Anhui Huaren Health Pharmaceutical Co., Ltd. was founded in 2001 and is based in Hefei, China.
Full company profileAnhui Huaren Health Pharmaceutical Co. Ltd. Cl A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.34B | 3.26B | 3.80B | 4.53B | 5.49B | 5.75B |
| Gross Profit | 815M | 1.06B | 1.16B | 1.48B | 1.86B | 1.98B |
| Operating Income | 123M | 245M | 182M | 257M | 413M | 457M |
| EBITDA | - | 403M | 389M | 530M | 661M | 430M |
| Net Income | 69.7M | 161M | 115M | 138M | 191M | 287M |
| EPS | 0.21 | 0.47 | 0.29 | 0.34 | 0.48 | 0.72 |
| Balance Sheet | ||||||
| Total Assets | 1.97B | 2.58B | 4.61B | 4.83B | 5.49B | 6.15B |
| Total Liabilities | 1.19B | 1.63B | 2.64B | 2.77B | 3.33B | 3.89B |
| Shareholders' Equity | 785M | 947M | 1.94B | 2.01B | 2.10B | 2.20B |
| Cash & Short-term Investments | 285M | 482M | 1.34B | 1,000M | 955M | 1.39B |
| Cash Flow | ||||||
| Operating Cash Flow | 141M | 174M | 131M | 572M | 837M | - |
| Capital Expenditure | 33.9M | 105M | 216M | 161M | 153M | 103M |
| Free Cash Flow | 107M | 69.1M | -84.9M | 411M | 684M | 753M |
| Ratios | ||||||
| ROE | 8.9% | 17.0% | 5.9% | 6.9% | 9.1% | 13.1% |
| ROA | 3.5% | 6.2% | 2.5% | 2.9% | 3.5% | 4.7% |
| Net Profit Margin | 3.0% | 4.9% | 3.0% | 3.0% | 3.5% | 5.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A dividends
- Dividend yield
- 1.00%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 29.7%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 56.7M | 0.14 | 29.7% |
| 2024 | CNY 56.0M | 0.14 | 40.7% |
| 2023 | CNY 14.7M | 0.04 | 12.8% |
| 2022 | CNY 4.13M | 0.01 | 2.6% |
| 2021 | CNY 4.34M | 0.01 | 6.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
- Insiders 60.99%
- Institutions 3.72%
- Public & others 35.29%
- Shares outstanding 400M
- Free float 142M
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A company profile
- Company name
- Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
- Ticker
- 301408.SHE
- ISIN
- CNE100005YT4
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 8,938
- Fiscal year end
- December
- Address
- Huaren Health Building, Hefei, China, 230051
- Phone
- 86 551 6286 2668
- Website
- hrjkjt.com
About Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
Anhui Huaren Health Pharmaceutical Co., Ltd. operates in the medical and healthcare industry. It offers products for oral and throat, nourishing, heat-clearing, respiratory system, and gynecology, as well as provides vitamins and minerals, and detoxifying products. In addition, it provides supplements, and nutrition and health products. Anhui Huaren Health Pharmaceutical Co., Ltd. was founded in 2001 and is based in Hefei, China.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A management
5- Mr. Jiale HeGM & Chairman of the Board · born 1976
- Ms. Mei LiCFO, Secretary & Accounting Supervisor · born 1977
- Mr. Jialun HeDeputy GM & Director · born 1973
- Mr. Jun YinDeputy GM & Director · born 1980
- Mr. Chunshui ZhaoDeputy GM & Employee Representative Director · born 1981